Free Trial

Medpace Q1 2024 Earnings Report

Medpace logo
$340.78 -4.07 (-1.18%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medpace EPS Results

Actual EPS
$3.20
Consensus EPS
$2.45
Beat/Miss
Beat by +$0.75
One Year Ago EPS
$2.27

Medpace Revenue Results

Actual Revenue
$511.00 million
Expected Revenue
$512.39 million
Beat/Miss
Missed by -$1.39 million
YoY Revenue Growth
+17.70%

Medpace Announcement Details

Quarter
Q1 2024
Time
After Market Closes

Conference Call Resources

Medpace Earnings Headlines

William Blair Has Bullish Forecast for Medpace Q1 Earnings
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
What is William Blair's Forecast for Medpace Q3 Earnings?
See More Medpace Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medpace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medpace and other key companies, straight to your email.

About Medpace

Medpace (NASDAQ:MEDP) engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

View Medpace Profile

More Earnings Resources from MarketBeat